HERON THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.7 USD | +7.25% |
|
+7.56% | +117.65% |
Presenter SpeechCraig Collard (Executives)Good morning, everyone. Welcome to the first ever He...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
Calendar
13/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.7
USD
Average target price
6.75
USD
Spread / Average Target
+82.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +117.65% | 557M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day
